Results 111 to 120 of about 25,901 (278)

Дерматологічні маркери гіперандрогенії та можливості їх корекції [PDF]

, 2017
Наведено дані щодо дерматологічних маркерів гіперандрогенії, їх клінічних проявів і механізмів виникнення. Розглянуто сучасні підходи до корекції гіперандрогенії шляхом використання комбінованих оральних контрацептивів у залежності від дерматологічних ...
Резніченко, Г.І., Резніченко, Н.Ю.   +1 more
core  

Effect of Central Obesity and Hyperandrogenism on Selected Inflammatory Markers in Patients with PCOS: A WHtR-Matched Case-Control Study [PDF]

, 2020
Małgorzata Kałużna, Magdalena Człapka-Matyasik, Katarzyna Wachowiak-Ochmańska, Jerzy Moczko, Jolanta Kaczmarek, Adam Janicki, Katarzyna Piątek, Marek Ruchała, Katarzyna Ziemnicka   +8 more
openalex   +1 more source

PENGARUH SUPLEMENTASI ISOFLAVON KEDELAI TERHADAP WANITA PENDERITA AKNE VULGARIS : Kajian Jumlah Lesi, Dihydrotestosterone, Toll-Like Receptor-2, dan Interleukin-8 [PDF]

, 2015
Latar belakang : Akne vulgaris (AV) merupakan penyakit inflamasi kulit yang paling sering dijumpai. Isoflavon kedelai telah terbukti sebagai antiandrogen dan antiinflamasi.
RIYANTO, Puguh
core  

Individual 17-Hydroxyprogesterone Responses to hCG Are Not Correlated With Follicle Size in Polycystic Ovary Syndrome. [PDF]

, 2019
Context:In women with polycystic ovary syndrome (PCOS), 17-hydroxyprogesterone (17-OHP) responses to gonadotropin stimulation vary from increased to indistinguishable compared with normal controls.
Chang, R Jeffrey, Duleba, Antoni J, Garzo, Gabriel, Homer, Michael V, Lawson, Mark A, Toloubeydokhti, Tannaz   +5 more
core   +1 more source

Hyperandrogen-induced imbalance of FOXO4-AR regulatory loop contributes to ovulatory disorders in polycystic ovary syndrome

Molecular Therapy: Nucleic Acids
Polycystic ovary syndrome (PCOS) is the leading cause of anovulatory infertility, and its underlying mechanisms remain largely unknown. Our study aimed to investigate the role of FOXO4 in PCOS and its possible regulatory mechanisms.
Ruiqiong Zhou, Zhaoyi Wang, Mei Dong, Songlu Wang, Xiangyuan Li, Junjiu Huang, Xiqian Zhang, Fenghua Liu   +7 more
doaj   +1 more source

Treatment of hyperandrogenism in women with ethinylestradiol and cyproteroneacetate [PDF]

, 2017
Alfred O. Mueck, on behalf of the global AWARE (Appropriate care for Women with AndRogen Excess) group   +1 more
openalex   +1 more source

Long-term environmental exposure of darkness induces hyperandrogenism in PCOS via melatonin receptor 1A and aromatase reduction [PDF]

, 2022
Weiwei Chu, Shang Li, Xueying Geng, Dongshuang Wang, Junyu Zhai, Gang Lü, Wai‐Yee Chan, Zi‐Jiang Chen, Yanzhi Du   +8 more
openalex   +1 more source

ODP416 Increased Ovarian Volume in Young Girls: A Marker of Impending Hyperandrogenism or Normal Variant? [PDF]

, 2022
Laura Golob, Asma Chattha, Siobhán T. Pittock   +2 more
openalex   +1 more source

A review on role of medicinal plants in polycystic ovarian syndrome: Pathophysiology, neuroendocrine signaling, therapeutic status and future prospects [PDF]

, 2018
Polycystic ovary syndrome (PCOS) is one of the most important gynecological disorders among reproductive-age women. In patients with PCOS, the secretion rate and metabolism of androgens and estrogens are disrupted.
Abasian, Z, Hosseini, M, Mohammadi, M, Rafieian-kopaei, M, Rostamzadeh, A   +4 more
core  

Exploring the Predictive Role of 11‐Oxyandrogens in Diagnosing Polycystic Ovary Syndrome

Endocrinology, Diabetes & Metabolism
Context Hyperandrogenism is a hallmark of polycystic ovary syndrome (PCOS), yet the androgen(s) responsible remain ambiguous. Recent studies have suggested that 11‐oxygenated C19 steroids (11‐oxyandrogens), specifically 11‐ketotestosterone, may be a good
Armaiti Parvez Mody, Maya Beth Lodish, Richard Joseph Auchus, Adina F. Turcu, Fei Jiang, Heather Gibson Huddleston   +5 more
doaj   +1 more source